Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.
about
HIV-1 polymerase inhibition by nucleoside analogs: cellular- and kinetic parameters of efficacy, susceptibility and resistance selectionIn vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysisCurrent and emerging formulation strategies for the effective transdermal delivery of HIV inhibitorsEffects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.Nuclear translocation as a novel target for anti-HIV drugs.Surveillance programs for detection and characterization of emergent pathogens and antimicrobial resistance: results from the Division of Infectious Diseases, UNIFESP.Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2.Tenofovir treatment augments anti-viral immunity against drug-resistant SIV challenge in chronically infected rhesus macaques.
P2860
Q28478993-FB02BF59-1A2B-4F84-A978-33EB5E56519BQ28486262-12CF4370-09AC-4460-981A-4357DCDB4F61Q28545757-77DBBA50-181B-48B7-A4F2-76AE2AFA88CCQ34058254-CADAED5E-0A3F-4327-A593-C4DD55226544Q35105844-B624CBD2-A3AF-48DA-A4A8-D2750AEB63CAQ36066205-74C5EABD-5027-49D4-A126-D5A6F12FCF2FQ37590197-9C11E403-F7F8-4916-A735-9E480A80DF0CQ40060575-56B98AB2-A975-4D0C-95D3-A35BDB0E1B07Q43011767-1021775D-7AD1-4001-94B1-62CA59D08C68
P2860
Understanding HIV resistance, fitness, replication capacity and compensation: targeting viral fitness as a therapeutic strategy.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Understanding HIV resistance, ...... ess as a therapeutic strategy.
@ast
Understanding HIV resistance, ...... ess as a therapeutic strategy.
@en
type
label
Understanding HIV resistance, ...... ess as a therapeutic strategy.
@ast
Understanding HIV resistance, ...... ess as a therapeutic strategy.
@en
prefLabel
Understanding HIV resistance, ...... ess as a therapeutic strategy.
@ast
Understanding HIV resistance, ...... ess as a therapeutic strategy.
@en
P2860
P1476
Understanding HIV resistance, ...... ess as a therapeutic strategy.
@en
P2093
Robert W Buckheit
P2860
P304
P356
10.1517/13543784.13.8.933
P407
P577
2004-08-01T00:00:00Z